Citigroup Downgrades Boston Scientific to Neutral, Cuts Target to $50
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 17, Citi downgraded its rating for Boston Scientific from Buy to Neutral and reduced its price target from $57 to $50. The downgrade reflects a shift in the bank's outlook on the medical device company's stock performance. The new price target implies a lower expected valuation compared to the previous target. The information was reported by Cailian Press, a Chinese financial news outlet.
Source report
Cailian Press, Sept. 17 — Citi has downgraded Boston Scientific's stock rating from Buy to Neutral, and reduced its price target from $57 to $50.
Source
财联社Neutral / independent
Part of this Story
Multiple Analysts Cut Boston Scientific Price Targets, Citi Downgrades to Neutral